Scotiabank initiated coverage of Vertex Pharmaceuticals (VRTX) with an Outperform rating and $495 price target Published first on TheFly – the ...
With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...
Vertex Pharmaceuticals chief Reshma Kewalramani said AI could reduce the time spent on drug-approval paperwork from months to ...
StockStory.org on MSN
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call
Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback